212 related articles for article (PubMed ID: 21041705)
1. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Sloand EM; Olnes MJ; Shenoy A; Weinstein B; Boss C; Loeliger K; Wu CO; More K; Barrett AJ; Scheinberg P; Young NS
J Clin Oncol; 2010 Dec; 28(35):5166-73. PubMed ID: 21041705
[TBL] [Abstract][Full Text] [Related]
2. Targeting immune dysregulation in myelodysplastic syndromes.
Olnes MJ; Sloand EM
JAMA; 2011 Feb; 305(8):814-9. PubMed ID: 21343581
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
6. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; de Witte T; Neukirchen J; Sekeres MA; Brunner AM; Roboz GJ; Steensma DP; Bhatt VR; Platzbecker U; Cluzeau T; Prata PH; Itzykson R; Fenaux P; Fathi AT; Smith A; Germing U; Ritchie EK; Verma V; Nazha A; Maciejewski JP; Podoltsev NA; Prebet T; Santini V; Gore SD; Komrokji RS; Zeidan AM
Blood Adv; 2018 Jul; 2(14):1765-1772. PubMed ID: 30037803
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
8. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
Scheinberg P; Nunez O; Weinstein B; Scheinberg P; Wu CO; Young NS
Blood; 2012 Jan; 119(2):345-54. PubMed ID: 22067384
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
Tholouli E; Liakopoulou E; Greenfield HM; Shaw BE; Tauro S; Byrne JL; Dennis M; Burthem J; Lucas GS; Craddock C; Russell NH; Liu Yin JA
Br J Haematol; 2008 Jun; 142(2):318-20. PubMed ID: 18492100
[No Abstract] [Full Text] [Related]
10. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
12. [Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics].
Doubek M; Jungová A; Brejcha M; Panovská A; Brychtová Y; Pospísil Z; Mayer J;
Vnitr Lek; 2009 Jun; 55(6):549-54. PubMed ID: 19662885
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
14. Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Selleri C; Serio B; Risitano AM
Mini Rev Med Chem; 2011 Jun; 11(6):536-43. PubMed ID: 21561402
[TBL] [Abstract][Full Text] [Related]
15. Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow.
Neukirchen J; Platzbecker U; Sockel K; Tsamaloukas A; Haas R; Germing U
Ann Hematol; 2014 Jan; 93(1):65-9. PubMed ID: 23934199
[TBL] [Abstract][Full Text] [Related]
16. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
17. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.
Kim H; Min YJ; Baek JH; Shin SJ; Lee EH; Noh EK; Kim MY; Park JH
Leuk Res; 2009 Feb; 33(2):222-31. PubMed ID: 18790532
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M; Erdel M; Tinhofer I; Brychtova Y; Panovska A; Doubek M; Eigenberger K; Fonatsch C; Hopfinger G; Mühlberger H; Zabernigg A; Falkner F; Gastl G; Mayer J; Greil R;
Ann Oncol; 2010 Dec; 21(12):2410-2419. PubMed ID: 20466745
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
